[1] Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma. Retrieved December 13, 2021, from https://www.janssen.com/janssen-presents-updated-results-evaluating-first-class-talquetamab-gprc5dxcd3-bispecific-antibody
[2] New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) in Treatment of Heavily Pretreated Patients with Multiple Myeloma. Retrieved December 13, 2021, from https://www.janssen.com/new-data-cartitude-1-study-show-continued-deep-and-durable-responses-ciltacabtagene-autoleucel-cilta
[3] Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting. Retrieved December 13, 2021, from https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-presents-positive-preclinical-data-selective
[4] NX‑5948, a Selective Degrader of BTK With Activity in Preclinical Models of Hematologic and Brain Malignancies. Retrieved December 13, 2021, from https://ir.nurixtx.com/static-files/4b347182-b738-4dce-87ec-b665486fe95b
[5] Tessa Therapeutics Showcases Positive Clinical Data from Phase 1 Study of “Off the Shelf” CD30 Cell Therapy at 2021 Annual Meeting of American Society of Hematology (ASH). Retrieved December 13, 2021, from https://www.tessacell.com/2021/12/12/tessa-therapeutics-showcases-positive-clinical-data-from-phase-1-study-of-off-the-shelf-cd30-cell-therapy-at-2021-annual-meeting-of-american-society-of-hematology-ash/
[6] Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL. Retrieved December 13, 2021, from https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-highlights-positive-durability-response-data
[7] Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting. Retrieved December 13, 2021, from https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-positive-results-phase-1-universal
[8] Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting. Retrieved December 13, 2021, from https://investor.lilly.com/news-releases/news-release-details/loxo-oncology-lilly-announces-updated-data-phase-12-bruin-1
[9] Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia. Retrieved December 13, 2021, from https://www.novartis.com/news/media-releases/novartis-scemblix-demonstrates-sustained-response-rate-48-week-follow-patients-chronic-myeloid-leukemia